Transthyretin Amyloidosis Treatment Market Top Players - American Express, Bank of America Corporation, Barclays PLC, Capital One, Citigroup Inc., JPMorgan Chase & Co.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Transthyretin Amyloidosis Treatment Market - (By Type (ATTR-PN, ATTR-CM), By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy), By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Transthyretin Amyloidosis Treatment Market is valued at US$ 5.2 billion in 2023, and it is expected to reach US$ 9.4 billion by 2031, with a CAGR of 7.90% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2890

Transthyretin amyloidosis treatment refers to the medical interventions used to treat and slow the progression of ATTR amyloidosis, an uncommon, progressive, and often fatal disease brought on by the buildup of abnormal transthyretin protein in tissues and organs. While medications are used to stabilize or lower transthyretin production, supportive therapy is utilized to address symptoms and issues. It is expected that the patient population receiving transthyretin amyloidosis treatment will benefit from the underdiagnosed state of transthyretin amyloidosis among patients with chronic diseases, as well as the increase in the number of diagnostic tests available to identify rare diseases. One of the main drivers boosting the transthyretin amyloidosis treatment market's growth is this, along with an increase in clinical studies to create pipeline medications for treating transthyretin amyloidosis and related illnesses. Additionally, it is projected that significant global government campaigns to raise awareness of transthyretin amyloidosis and its treatment-which are backed by patient reimbursements-will boost the uptake of therapies and promote market expansion.

List of Prominent Players in the Transthyretin Amyloidosis Treatment Market:
• Acrotech Biopharma, LLC
• Alnylam Pharmaceuticals, Inc.
• AstraZeneca PLC
• Astellas Pharma Inc.
• BridgeBio Pharma, Inc.
• Bristol-Myers Squibb Company
• Ionis Pharmaceuticals, Inc.
• Johnson & Johnson
• Prothena Biosciences Limited
• Pfizer Inc.
• SOM Innovation Biotech, S.L.
• Abbvie, Inc.
• Sanofi
• Eidos Therapeutics, Inc
• BELLUS Health Inc

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-03

Market Dynamics:
Drivers-
In light of the fact that the elderly population is expanding at a rate of 16%, which is expected to reach 1.5 billion in the future. There is a growing market need for transthyretin amyloidosis as a result of the increasing occurrence of the disease, particularly in the geriatric population. According to the Prothena article, over 400,000 people worldwide have ATTRwt amyloidosis, while roughly 50,000 people have hATTR amyloidosis. The heart is the primary organ affected by an age-related variant of wild-type ATTR amyloidosis, according to NCBI data. A significant risk factor for amyloidosis of the wild type is ageing (ATTRwt). Awareness of transthyretin amyloidosis and its treatment has been raised by a number of initiatives. For instance, to increase awareness among medical professionals and patients with ATTR amyloidosis, the Australian Amyloidosis Network arranged a biennial touring workshop.

Challenges:
The market for transthyretin amyloidosis treatments is hampered by healthcare providers' ignorance, which results in patients receiving incorrect treatment. It is anticipated that the high price of recently approved medications will hurt the market. For instance, according to a study by Alnylam Pharmaceuticals, Inc., the price of the recently approved medication Patisiran is approximately $450,000 USD. Inotersen, another medication, has an annual value of USD 450,000.

Regional Trends:
The North American transthyretin amyloidosis treatment market is anticipated to note a major market share in terms of revenue. The market for transthyretin amyloidosis treatments is being driven primarily by expanding medicine prescriptions for the condition as well as increased treatment rates. The transthyretin amyloidosis treatment market in the region was significantly impacted by Health Canada's approval of the medication ONPATTRO for the treatment of hATTR polyneuropathy. Besides, the Middle East and Africa had a substantial share of the market. In the upcoming years, the market is anticipated to be driven by high unmet treatment demands, rising approval rates, and rising illness prevalence. Significant elements include a sizable target population, sound healthcare reforms, and a rise in illness awareness, which are also anticipated to be the main drivers of growth.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2890

Segmentation of Transthyretin Amyloidosis Treatment Market-
By Type-
• ATTR-PN
• ATTR-CM
By Therapy-
• Targeted Therapy
o Onpattro
o Inotersen
o Vyndaqel/Vyndamax
• Supportive Therapy
• Pipeline Therapy
By Disease Type-
• Hereditary Transthyretin Amyloidosis
o Polyneuropathy
o Cardiomyopathy
o Mixed Type
• Wild Type Amyloidosis
By Distribution Channel-
• Hospital Pharmacies
• Specialty Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.